NUTRIBAND INC. DL -001
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops AVERSA b… Read more
Market Cap & Net Worth: NUTRIBAND INC. DL -001 (9WV)
NUTRIBAND INC. DL -001 (F:9WV) has a market capitalization of $37.00 Million (€36.05 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #27620 globally and #3025 in its home market, demonstrating a -13.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying NUTRIBAND INC. DL -001's stock price €3.00 by its total outstanding shares 12015983 (12.02 Million).
NUTRIBAND INC. DL -001 Market Cap History: 2021 to 2026
NUTRIBAND INC. DL -001's market capitalization history from 2021 to 2026. Data shows change from $32.77 Million to $37.00 Million (-13.81% CAGR).
NUTRIBAND INC. DL -001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how NUTRIBAND INC. DL -001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9WV by Market Capitalization
Companies near NUTRIBAND INC. DL -001 in the global market cap rankings as of March 19, 2026.
Key companies related to NUTRIBAND INC. DL -001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
NUTRIBAND INC. DL -001 Historical Marketcap From 2021 to 2026
Between 2021 and today, NUTRIBAND INC. DL -001's market cap moved from $32.77 Million to $ 37.00 Million, with a yearly change of -13.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €37.00 Million | -32.13% |
| 2025 | €54.52 Million | +22.10% |
| 2024 | €44.65 Million | +69.16% |
| 2023 | €26.39 Million | -36.69% |
| 2022 | €41.69 Million | +27.21% |
| 2021 | €32.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of NUTRIBAND INC. DL -001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.00 Million USD |
| MoneyControl | $37.00 Million USD |
| MarketWatch | $37.00 Million USD |
| marketcap.company | $37.00 Million USD |
| Reuters | $37.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.